Annual EBITDA
-$447.31 M
-$244.61 M-120.67%
December 31, 2024
Summary
- As of February 21, 2025, CRSP annual EBITDA is -$447.31 million, with the most recent change of -$244.61 million (-120.67%) on December 31, 2024.
- During the last 3 years, CRSP annual EBITDA has fallen by -$838.79 million (-214.26%).
- CRSP annual EBITDA is now -214.26% below its all-time high of $391.48 million, reached on December 31, 2021.
Performance
CRSP EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$59.75 M
+$45.65 M+43.31%
December 31, 2024
Summary
- As of February 21, 2025, CRSP quarterly EBITDA is -$59.75 million, with the most recent change of +$45.65 million (+43.31%) on December 31, 2024.
- Over the past year, CRSP quarterly EBITDA has increased by +$86.67 million (+59.19%).
- CRSP quarterly EBITDA is now -107.80% below its all-time high of $766.27 million, reached on June 30, 2021.
Performance
CRSP Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$447.31 M
-$134.23 M-42.87%
December 31, 2024
Summary
- As of February 21, 2025, CRSP TTM EBITDA is -$447.31 million, with the most recent change of -$134.23 million (-42.87%) on December 31, 2024.
- Over the past year, CRSP TTM EBITDA has dropped by -$112.13 million (-33.46%).
- CRSP TTM EBITDA is now -197.41% below its all-time high of $459.18 million, reached on June 30, 2021.
Performance
CRSP TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CRSP EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -120.7% | +59.2% | -33.5% |
| 3 y3 years | -214.3% | +59.2% | -33.5% |
| 5 y5 years | -969.1% | +59.2% | -33.5% |
CRSP EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -214.3% | +31.1% | -180.2% | +66.3% | -214.3% | +32.5% |
| 5 y | 5-year | -214.3% | +31.1% | -107.8% | +66.3% | -197.4% | +32.5% |
| alltime | all time | -214.3% | +31.1% | -107.8% | +66.3% | -197.4% | +32.5% |
CRISPR Therapeutics AG EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$447.31 M(+120.7%) | -$59.75 M(-43.3%) | -$447.31 M(+42.9%) |
| Sep 2024 | - | -$105.39 M(-28.0%) | -$313.08 M(-6.6%) |
| Jun 2024 | - | -$146.41 M(+7.9%) | -$335.17 M(+20.1%) |
| Mar 2024 | - | -$135.75 M(-282.3%) | -$279.02 M(+37.7%) |
| Dec 2023 | -$202.70 M(-68.8%) | $74.48 M(-158.4%) | -$202.70 M(-49.7%) |
| Sep 2023 | - | -$127.49 M(+41.2%) | -$402.88 M(-11.0%) |
| Jun 2023 | - | -$90.26 M(+51.9%) | -$452.76 M(-15.9%) |
| Mar 2023 | - | -$59.44 M(-52.7%) | -$538.49 M(-17.0%) |
| Dec 2022 | -$648.99 M(-265.8%) | -$125.69 M(-29.1%) | -$648.99 M(-2.1%) |
| Sep 2022 | - | -$177.37 M(+0.8%) | -$662.73 M(+8.8%) |
| Jun 2022 | - | -$175.99 M(+3.6%) | -$608.89 M(-282.6%) |
| Mar 2022 | - | -$169.93 M(+21.9%) | $333.38 M(-14.8%) |
| Dec 2021 | $391.48 M(-213.4%) | -$139.44 M(+12.9%) | $391.48 M(-8.0%) |
| Sep 2021 | - | -$123.53 M(-116.1%) | $425.72 M(-7.3%) |
| Jun 2021 | - | $766.27 M(-785.2%) | $459.18 M(-219.1%) |
| Mar 2021 | - | -$111.83 M(+6.3%) | -$385.58 M(+11.7%) |
| Dec 2020 | -$345.25 M | -$105.19 M(+16.8%) | -$345.25 M(+51.7%) |
| Sep 2020 | - | -$90.06 M(+14.7%) | -$227.64 M(-8034.5%) |
| Jun 2020 | - | -$78.50 M(+9.8%) | $2.87 M(-89.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$71.50 M(-675.9%) | $27.58 M(-46.4%) |
| Dec 2019 | $51.47 M(-133.1%) | $12.41 M(-91.2%) | $51.47 M(-1083.5%) |
| Sep 2019 | - | $140.45 M(-361.1%) | -$5.23 M(-97.3%) |
| Jun 2019 | - | -$53.78 M(+13.0%) | -$194.23 M(+9.8%) |
| Mar 2019 | - | -$47.61 M(+7.5%) | -$176.86 M(+13.8%) |
| Dec 2018 | -$155.42 M(+152.2%) | -$44.28 M(-8.8%) | -$155.42 M(+42.1%) |
| Sep 2018 | - | -$48.55 M(+33.3%) | -$109.36 M(+30.8%) |
| Jun 2018 | - | -$36.42 M(+39.2%) | -$83.59 M(+23.3%) |
| Mar 2018 | - | -$26.17 M(-1571.9%) | -$67.77 M(+10.0%) |
| Dec 2017 | -$61.62 M(+348.4%) | $1.78 M(-107.8%) | -$61.62 M(+35.5%) |
| Sep 2017 | - | -$22.78 M(+10.6%) | -$45.49 M(+22.4%) |
| Jun 2017 | - | -$20.60 M(+2.9%) | -$37.16 M(+10.7%) |
| Mar 2017 | - | -$20.02 M(-211.8%) | -$33.56 M(+144.2%) |
| Dec 2016 | -$13.74 M(-46.3%) | $17.91 M(-223.9%) | -$13.74 M(-68.6%) |
| Sep 2016 | - | -$14.45 M(-15.0%) | -$43.71 M(+23.4%) |
| Jun 2016 | - | -$16.99 M(+7991.9%) | -$35.41 M(+92.2%) |
| Mar 2016 | - | -$210.00 K(-98.3%) | -$18.42 M(+1.2%) |
| Dec 2015 | -$25.59 M(+274.9%) | -$12.06 M(+96.0%) | -$18.21 M(+196.0%) |
| Sep 2015 | - | -$6.15 M | -$6.15 M |
| Dec 2014 | -$6.83 M | - | - |
FAQ
- What is CRISPR Therapeutics AG annual EBITDA?
- What is the all time high annual EBITDA for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG annual EBITDA year-on-year change?
- What is CRISPR Therapeutics AG quarterly EBITDA?
- What is the all time high quarterly EBITDA for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG quarterly EBITDA year-on-year change?
- What is CRISPR Therapeutics AG TTM EBITDA?
- What is the all time high TTM EBITDA for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG TTM EBITDA year-on-year change?
What is CRISPR Therapeutics AG annual EBITDA?
The current annual EBITDA of CRSP is -$447.31 M
What is the all time high annual EBITDA for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high annual EBITDA is $391.48 M
What is CRISPR Therapeutics AG annual EBITDA year-on-year change?
Over the past year, CRSP annual EBITDA has changed by -$244.61 M (-120.67%)
What is CRISPR Therapeutics AG quarterly EBITDA?
The current quarterly EBITDA of CRSP is -$59.75 M
What is the all time high quarterly EBITDA for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high quarterly EBITDA is $766.27 M
What is CRISPR Therapeutics AG quarterly EBITDA year-on-year change?
Over the past year, CRSP quarterly EBITDA has changed by +$86.67 M (+59.19%)
What is CRISPR Therapeutics AG TTM EBITDA?
The current TTM EBITDA of CRSP is -$447.31 M
What is the all time high TTM EBITDA for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high TTM EBITDA is $459.18 M
What is CRISPR Therapeutics AG TTM EBITDA year-on-year change?
Over the past year, CRSP TTM EBITDA has changed by -$112.13 M (-33.46%)